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Abstract
Background: The inflammatory response is prominent in the pathogenesis of dermal leishmaniasis. We hypothesized that
regulatory T cells (Tregs) may be diminished in chronic dermal leishmaniasis (CDL) and contribute to healing during
treatment.
Methodology/Principal Findings: The frequency and functional capacity of Tregs were evaluated at diagnosis and
following treatment of CDL patients having lesions of $6 months duration and asymptomatically infected residents of
endemic foci. The frequency of CD4
+CD25
hi cells expressing Foxp3 or GITR or lacking expression of CD127 in peri-
pheral blood was determined by flow cytometry. The capacity of CD4
+CD25
+ cells to inhibit Leishmania-specific responses
was determined by co-culture with effector CD4
+CD25
2 cells. The expression of FOXP3, IFNG, IL10 and IDO was determined
in lesion and leishmanin skin test site biopsies by qRT-PCR. Although CDL patients presented higher frequency of
CD4
+CD25
hiFoxp3
+ cells in peripheral blood and higher expression of FOXP3 at leishmanin skin test sites, their CD4
+CD25
+
cells were significantly less capable of suppressing antigen specific-IFN-c secretion by effector cells compared with
asymptomatically infected individuals. At the end of treatment, both the frequency of CD4
+CD25
hiCD127
2 cells and their
capacity to inhibit proliferation and IFN-c secretion increased and coincided with healing of cutaneous lesions. IDO was
downregulated during healing of lesions and its expression was positively correlated with IFNG but not FOXP3.
Conclusions/Significance: The disparity between CD25
hiFoxp3
+ CD4 T cell frequency in peripheral blood, Foxp3 expression
at the site of cutaneous responses to leishmanin, and suppressive capacity provides evidence of impaired Treg function in
the pathogenesis of CDL. Moreover, the concurrence of increased Leishmania-specific suppressive capacity with induction
of a CD25
hiCD127
2 subset of CD4 T cells during healing supports the participation of Tregs in the resolution of chronic
dermal lesions. Treg subsets may therefore be relevant in designing immunotherapeutic strategies for recalcitrant dermal
leishmaniasis caused by Leishmania (Viannia) species.
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Introduction
Dermal leishmaniasis (DL) caused by species from the Viannia
subgenus is characterized by a paucity of parasites in lesions
associated with a robust inflammatory response and frequently
follows a chronic course [1]. Both cutaneous and muco-cutaneous
presentations of chronic dermal leishmaniasis (CDL) caused by
Leishmania (Viannia) are associated with elevated cellular immune
responses [2,3]. Human studies and a recent murine model of
chronic dermal disease have shown that a mixed Th1/Th2
cytokine pattern occurs in CDL caused by L. (Viannia), with
prominent secretion of IFN-c, IL-13, IL-10 and TNF-a [4–6].
Even though regulatory mechanisms are likely to have a significant
role in the development of such an immune response, little is
known about their impact in determining susceptibility and
shaping disease outcome.
Regulatory T cells (Tregs) maintain tolerance to self tissues by
inhibiting the action of auto-antigen reactive lymphocytes in an
antigen-specific manner. In infectious diseases, Tregs also regulate
the intensity and duration of immune responses, limiting damage
to self tissues [7–8]. In the murine model of DL caused by L. major,
Tregs have been shown to promote parasite persistence and
reactivation in the resistant strain C57Bl/6 while inhibiting
pathology in the susceptible Balb/c strain [9–12]. Tregs also
suppressed pathology in mouse strains susceptible to disease
caused by L. amazonensis [13]. These observations indicate that
www.plosntds.org 1 April 2012 | Volume 6 | Issue 4 | e1627regulation of Leishmania-specific responses by Tregs may differen-
tially alter the outcome of infection according to the susceptibility
phenotype dictated by the host response. In resistant individuals,
excessive Treg action may interfere with elimination of infection,
whereas in susceptible individuals deficient Treg function may lead
to excessive inflammation and dermal pathology.
Studies in humans infected with species from the Viannia
subgenus have demonstrated that T cells with regulatory
phenotype and function are present in cutaneous lesions [14–
17]. An association between increased Foxp3 expression and
unresponsiveness to treatment and chronic disease has been
reported in human DL caused by L. guyanensis infection [16–17]. In
contrast, no differences were found in the frequency of Tregs in
peripheral blood between asymptomatically infected individuals
(AI) and patients with CDL in L. braziliensis infection [14]. Hence,
the role of Tregs in the pathogenesis of DL and their participation
in the therapeutic response remain unclear.
The purpose of this study was to evaluate the role of Tregs in
CDL caused by species of the Viannia subgenus and in the
resolution of chronic lesions following treatment with pentavalent
antimony. We found that lack of regulation of IFN-c secretion by
Tregs was associated with development of chronic disease, while
an increase of Treg function after treatment was associated with
lesion healing.
Methods
Experimental Strategy and Rationale
In this study, asymptomatic infection was considered to
approximate clinical resistance to natural infection, and chronic
disease to define a clinically susceptible phenotype, analogous to
the healing and non-healing phenotypes in murine models of
cutaneous leishmaniasis. Because AI and DL patients evidently
remain infected indefinitely [18–23], exposure to Leishmania
antigens would persist in both clinical outcomes. Since DL is
generally a self-resolving disease, discrimination of spontaneous
healing and chronic disease is not reliably determined during early
or intermediate stages of evolution. However, longer times of
evolution (chronic disease) have been shown to be associated with
increased immune reactivity to Leishmania antigens including
significantly higher antibody titers and DTH responses [2].
Furthermore, Th1/Th2 transcription factor expression and
inflammatory cytokine responses distinguished asymptomatic
clinical outcome and chronic cutaneous disease [5]. The rationale
for analyzing the Treg response in asymptomatic infection and
chronic disease was, therefore, that these phenotypically distin-
guishable outcomes are natural expressions of clinical resistance
and susceptibility to human dermal leishmaniasis.
Ethics Statement
All participants provided written informed consent. The study
protocol, consent forms and all procedures were approved by the
CIDEIM Institutional Review Board for the ethical conduct of
research involving human subjects.
Human Subjects
Participants were residents of endemic areas for L. panamensis
and L. braziliensis located within the southwestern Pacific coast
region of Colombia (Departments of Valle del Cauca and Narin ˜o)
[24]. We included cases caused by both of these species of the
Viannia subgenus because there is significant overlap of clinical
presentations and broad measures of immune responses (DTH,
lymphocyte proliferation and antibody titer) in patients with
dermal disease caused by these species [2,25]. AI had a positive
LST and no evidence or history of dermal lesions. CDL patients
had dermal lesions of $6 months duration, parasitological
diagnosis by microscopic examination of tissue samples from
lesions, culture or biopsy, and had not received anti-leishmanial
treatment before enrollment. All subjects had negative serology for
HIV and HTLV-1. A LST was performed in all participants and
evaluated at 48 hours as previously described [26]. Leishmanin
(Instituto Nacional de Salud, Colombia) was composed of equal
amounts of L. panamensis and L. amazonensis promastigote proteins
at a concentration of 5 mg/mL. Peripheral blood samples
(100 mL), and skin biopsies from a leishmaniasis lesion and LST
reaction site were obtained upon entry into the study. The species
of parasite strains isolated from patients with a positive culture
were determined as previously described [27]. CDL patients were
treated with meglumine antimoniate at a dose of 20 mg Sb/kg/
day. After treatment, a second 100 mL blood sample and a biopsy
from the same lesion site were obtained and clinical responses
were evaluated. Complete healing was defined as total re-
epithelialization and absence of any evidence of inflammation
for all lesions. Partial healing was estimated as the percentage of
reduction of ulcer/plaque area or nodule volume. Skin biopsies
from four healthy volunteers were obtained for normalization of
gene expression data. Biopsies were obtained using a 4 mm
disposable punch, embedded in OCT, frozen and stored in liquid
nitrogen until processed.
Cell Isolation
PBMCs were isolated by centrifugation over Histopaque-1077
(Sigma-Aldrich, St. Louis, MO). CD4
+CD25
2 and CD4
+CD25
+
cells were isolated by MACS using the CD4
+CD25
+ Regulatory T
cell isolation kit (Miltenyi Biotec, Bergisch-Gladbach, Germany)
following the manufacturer’s instructions. Purity assessed by
staining with anti-CD4 and anti-CD25 was $90% for both
populations. Monocytes were isolated by allowing PBMCs to
adhere to plastic for 2 hours followed by three washes with PBS.
Purity assessed by staining with anti-CD14 was $65% and
contaminating CD4
hi lymphocytes were ,5%.
Author Summary
The immune inflammatory response is a double edged
sword. During infectious diseases, regulatory T cells can
prevent eradication of the pathogen but can also limit
inflammation and tissue damage. We investigated the role
of regulatory T cells in chronic dermal leishmaniasis caused
by species of the parasite Leishmania that are endemic in
South and Central America. We found that although
individuals with chronic lesions have increased regulatory
T cells in their blood and at skin sites where immune
responses to Leishmania were taking place compared to
infected individuals who do not develop disease, their
capacity to control the inflammatory response to Leish-
mania was inferior. However, healing of chronic lesions at
the end of treatment was accompanied by an increase in
the number and capacity of regulatory T cells to inhibit the
function of effector T cells that mediate the inflammatory
response. Different subsets of regulatory T cells, defined by
the expression of molecular markers, were identified
during chronic disease and healing, supporting the
participation of distinct regulatory T cells in the develop-
ment of disease and the control of inflammation during
the healing response. Immunotherapeutic strategies may
allow these regulatory T cell subsets to be mobilized or
mitigated to achieve healing.
Tregs in Dermal Leishmaniasis
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PBMCs from 12 AI, 14 CDL patients before treatment, and 11
CDL patients after treatment were suspended in FACS buffer (16
PBS,1%BSA,0.1%NaN3) andincubatedfor30 minutes with anti-
CD4-APC (BD Biosciences, San Jose, CA), anti-CD25-PE (Miltenyi
Biotec) and anti-CD127-FITC (eBioscience, San Diego, CA) or
anti-CD4-FITC (BD Biosciences), anti-glucocorticoid-induced
TNF receptor family-related protein (GITR)-PE and anti-CD25-
APC (eBioscience). For evaluation of forkhead box p3 (Foxp3), cells
were stained with anti-CD4-FITC and anti-CD25-APC, fixed and
permeabilized using the Fixation and Permeabilization kit (eBios-
ciences), and incubated with anti-Foxp3-PE or anti-Rat IgG2a-PE
(eBioscience). After washing, cells were analyzed in a Navios flow
cytometer (Beckman Coulter, Brea, CA) and data was analyzed
using FlowJo 7.6 software (Tree Star, Inc., Ashland, OR). Gates
used for analysis were set using isotype controls.
Co-Culture of CD4
+CD25
2 and CD4
+CD25
+ Cells
Killed promastigotes of the L. panamensis strain MHOM/COL/
81/L13 were prepared by the freeze/thaw method, as previously
described [28]. CD4
+CD25
2 cells from 12 AI, 14 CDL patients
before treatment, and 11 CDL patients after treatment were
incubated with 5 mM carboxyfluorescein diacetate succinimidyl
diester (CFSE, Invitrogen, Carlsbad, CA) for 10 minutes at 4uC,
washed three times with PBS and resuspended in RMPI 1640
(Sigma-Aldrich) with 10% FBS (Gibco, Carlsbad, CA), 2 mM L-
glutamine, penicillin (100 U/mL) and streptomycin (100 mg/mL).
1610
6 CD4
+CD25
2 cells per well were distributed in 24 well plates
with 2610
5 L. panamensis promastigotes, 5610
5 monocytes from the
same subject (used as antigen presenting cells, APCs), or
phytohaemagglutinin (PHA, Sigma-Aldrich) 10 mg/mL, and
CD4
+CD25
+ cells at 1:0, 4:1 or 1:1 CD4
+CD25
2: CD4
+CD25
+
cell ratios, in a final volume of 1 mL. After 5 days of incubation at
37uC with 5% CO2, cells and supernatants were harvested for
evaluationof proliferation and cytokinesecretion, respectively. Cells
were stained with anti-CD4-APC and analyzed by flow cytometry.
CFSEfluorescenceinCD4
+CD25
2 cellswasevaluatedintheCD4
+
gate. Unlabeled CD4
+CD25
+ cells and CD4
+ lymphocytes
contaminating the APC preparation were gated out of the analysis
(Figure S1A). Regions were drawn for each proliferation peak
induced by PHA (Figure S1B) and the proliferation index (PI) was
calculated with the formula PI=S(% in region62
n21), where n is
the region number [29]. Interferon-c (IFN-c) and interleukin-10
(IL-10) were measured in supernatants by ELISA as previously
described [28]. Co-cultures were considered to have positive
proliferation or IFN-c secretion when the value in wells with
CD4
+CD25
2 cells, APCs and L. panamensis or PHA was higher than
the mean+2SD of the control wells without APCs, L. panamensis or
neither. The percent inhibition of proliferation or IFN-c secretion
by CD4
+CD25
+ cells was calculatedin positiveco-cultures using the
formula:(valuewithout CD4
+CD25
+ cells- value with CD4
+CD25
+
cells)/(value without CD4
+CD25
+ cells) 6100. Negative results
were considered 0% inhibition.
Real-Time PCR Analysis
RNA was isolated from LST biopsies from 5 AI and 7 CDL
patients and lesion biopsies from 11 CDL patients both before and
after treatment using the RNeasy mini kit (QIAGEN, Valencia,
CA) according to the manufacturer’s instructions. For cDNA
synthesis, 100 ng total RNA was transcribed with the High-
capacity cDNA reverse transcription kit (Applied Biosystems,
Foster City, CA), following the manufacturer’s instructions. Gene
expression was measured in real-time with the CFX966 Real Time
System (Bio-Rad, Hercules, CA) using Taqman Universal PCR
master mix and Taqman gene expression assays for GAPDH
(Hs99999905m-1), FOXP3 (Hs01085835-m1), IFNG (Hs00174143-
m1), IL10 (Hs00174086-m1) and IDO (Hs00158027-m1) genes
(Applied Biosystems), following the manufacturer’s instructions.
The expression levels of FOXP3, IFNG, IL10 and IDO relative to
healthy skin were calculated using the DDCT method, as
previously described [30], using GAPDH as endogenous reference
gene and four healthy skin biopsies as calibrators.
Statistical Analysis
The Kolmogorov-Smirnov test was used to determine para-
metric or non-parametric distribution of the data. Thereafter, for
comparisons between AI and CDL patients, parametric data were
analyzed using student t-test, and the Mann-Whitney test was
applied for non-parametric data. For comparisons between CDL
patients before and after treatment, parametric and non-
parametric data were analyzed using the paired t-test and the
Wilcoxon signed-rank test, respectively. Correlation analyses were
conducted using the Spearman coefficient. Statistical significance
was defined as p,0.05. All data were analyzed using Prism 5
software (GraphPad Software, Inc., La Jolla, CA).
Results
Clinical Characteristics of the Study Subjects
Twelve AI and 14 CDL patients participated in this study.
There were no significant differences in age, gender or size of LST
reaction between AI and CDL patients (data not shown). The
clinical characteristics of CDL patients are summarized in Table 1.
Three patients were lost to follow-up. The other eleven patients
were evaluated at a second visit within 24 days of completing
treatment. Five patients showed complete healing, and lesions in
six patients had substantially improved though not completely
healed (Table 1).
CDL Patients Presented a Higher Frequency of
CD4
+CD25
hiFoxp3
+ Cells in Peripheral Blood than AI
High expression of CD25 has been described as a reliable
marker for Tregs [31–34]. Lack of expression of CD127,
expression of GITR, or expression of Foxp3 have also been
described as Treg markers [34–37]. Therefore, to evaluate the
frequency of Tregs in the peripheral blood of AI and CDL
patients, we measured the frequency of CD25
hi CD4 T cells that
expressed each of these markers. We found that CD4
+CD25
hi-
Foxp3
+ cells were more abundant in the peripheral blood of CDL
patients (0.960.4% in CDL patients vs. 0.460.2 in AI, p=0.0003;
Figure 1A), while significant differences were not observed in the
frequency of CD4
+CD25
hiCD127
2 and CD4
+CD25
hiGITR
+ cells
between the two groups (Figures 1B and C).
CD4
+CD25
+ Cells from AI Demonstrated a Higher
Capacity to Suppress CD4 Effector T Cell IFN-c Secretion
than Those from CDL Patients
We evaluated the functional capacity of Tregs to suppress
Leishmania-specific proliferation and IFN-c secretion using co-
cultures of CD4
+CD25
2 cells (effectors) and CD4
+CD25
+ cells
(Tregs) from peripheral blood. In the absence of Tregs,
proliferation and IFN-c secretion were induced by L. panamensis
antigens in effector T cells from all CDL patients and 9 of 12 AI.
Proliferation was significantly higher for CDL patients in relation
to AI (p=0.037, Figure 2A), while no statistically significant
differences were detected for IFN-c secretion (Figure 2B). No
significant effector functions were observed in the absence of either
Tregs in Dermal Leishmaniasis
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they were the result of antigen-specific APC-T cell interactions. L.
panamensis induced similar levels of proliferation and IFN-c
secretion in patients infected with L. panamensis or L. braziliensis
and in patients in which infecting species was undetermined (data
not shown), confirming recall of T cell responses across species.
High levels of proliferation were induced by PHA in all subjects
(Figure 2A), while IFN-c secretion was low with this stimulus
under the conditions of assay (Figure 2B), being positive only for 6
AI and 3 CDL patients.
Suppression assays with L. panamensis stimulation were per-
formed at effector:Treg ratios of 4:1 and 1:1 in subjects that had
positive effector functions, except for three AI from whom the
number of CD4
+CD25
+ cells isolated was insufficient to evaluate
the 1:1 ratio. At a 4:1 effector:Treg ratio, no statistically significant
differences in antigen-specific suppression were detected between
AI and CDL patients (Figures 2C and D). At a 1:1 effector:Treg
ratio, suppression of IFN-c secretion was significantly higher in AI
compared to CDL patients (8066.1% vs. 4869.2%, p=0.044;
Figure 2D) whereas suppression of proliferation was not
significantly different between the two groups (Figure 2C). To
evaluate suppression after a polyclonal stimulus, inhibition of
proliferation by Tregs at a 4:1 ratio was evaluated after PHA
stimulation. No significant differences in suppression of prolifer-
ation induced by PHA were detected between AI and CDL
patients (mean inhibition 19.564.1% and 25.965.8%, respective-
ly; p=0.313; Figure 2C).
FOXP3 Expression Is Higher in LST Sites of CDL Patients
than AI
We next examined the influence of Tregs in situ by measuring
the transcription of genes related to immune regulation and
Table 1. Clinical characteristics and evolution of chronic dermal leishmaniasis patients.
Subject
code
Isolated
parasite
Lesion
duration
(months)
Lesion
number Lesion Type
Time of second sample
(Days after treatment) % Cured
a
111 ND 8 1 Nodule 2 50
112 L. braziliensis 6 2 Ulcers 1 100
113 L. panamensis 7 1 Ulcer Lost to followup NA
114 L. panamensis 6 3 Ulcers Lost to followup NA
116 L. panamensis 6 5 Ulcers/plaque/mucosal 1 80
117 L. panamensis 18 8 Plaques/papules/mucosal 24 100
118 L. panamensis 6 1 Ulcer Lost to followup NA
121 L. panamensis 20 3 Plaques/Nodule 1 90
209 ND 6 1 Ulcer 5 100
214 ND 24 1 Ulcer 2 60
216 L. braziliensis 240 1 Ulcer 2 80
217 L. panamensis 36 1 Plaque 2 100
218 ND 48 1 Ulcer 2 80
223 ND 6 3 Plaques 23 100
a% of surface area of ulcer(s) or plaque(s) healed or volume of nodule(s) reduced at the end of treatment; ND: not determined because culture was not necessary or no
strain was obtained; NA: not applicable.
doi:10.1371/journal.pntd.0001627.t001
Figure 1. CDL patients have a higher frequency of CD4
+CD25
hiFoxP3
+ cells in peripheral blood than AI. PBMCs from AI (n=12) and CDL
patients (n=14) were stained for CD4, CD25 and either Foxp3, CD127, or GITR and analyzed by flow cytometry. A. Frequency of CD4
+CD25
hiFoxp3
+
cells. B. Frequency of CD4
+CD25
hiCD127
2 cells. C. Frequency of CD4
+CD25
hiGITR
+ cells. ***p,0.001, Mann-Whitney test. The median is represented
by a horizontal line.
doi:10.1371/journal.pntd.0001627.g001
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AI and 7 CDL patients. We evaluated the relative expression of
four genes: FOXP3, IFNG, IL10, and 2,3 indoleamine deoxygen-
ase (IDO), an enzyme expressed by APCs that is involved in
immune regulation through the catabolism of the essential
aminoacid tryptophan [38,39]. We found that the relative
expression of FOXP3 was significantly higher in CDL patients
in relation to AI (relative expression 12.764.3 vs. 0.760.8,
p=0.046, Figure 3A). No statistically significant differences were
found for the other genes, although several individuals with
chronic disease showed upregulation of IFNG and IDO
(Figures 3B–D).
CD4
+CD25
hiCD127
2 Cells and Suppression by
CD4
+CD25
+ Cells Increased after Treatment of CDL
At the end of treatment of CDL, the proportion of
CD4
+CD25
hiCD127
2 cells increased significantly, from
1.560.2% to 2.360.3% (p=0.0009, Figure 4B), whereas the
frequency of CD4
+CD25
hiFoxp3
+ and CD4
+CD25
hiGITR
+ cells
did not change significantly (Figure 4A and C). Proliferation and
IFN-c secretion in the absence of Tregs did not change
significantly at the end of treatment, although significant
proliferation was no longer observed in one patient (data not
shown). In the presence of Tregs at a 1:1 effector:Treg ratio, 8 of
10 CDL patients demonstrated increased inhibition of prolifera-
Figure 2. CD4
+CD25
+ cells from AI have a higher capacity to suppress IFN-c secretion by effector cells. CD4
+CD25
2 (effector) cells from
AI (n=12) and CDL patients (n=14) were cultured for 5 days with antigen presenting cells (APCs), L. panamensis (L.p.), or both, or with PHA, as
indicated. A. Proliferation of CD4
+CD25
2 cells. B. IFN-c levels secreted by CD4
+CD25
2 cells. Positive proliferation and IFN-c secretion were defined as
levels above the mean+2SD of control wells from the same donor. For subjects whose effector cells showed positive proliferation and IFN-c secretion
(n=9 for AI and n=14 for CDL patients, L.p.+APCs stimulation; n=12 for AI and n=14 for CDL patients, PHA stimulation), cultures were conducted in
the presence or absence of CD4
+CD25
+ (regulatory) cells. C. Inhibition of CD4
+CD25
2 cell proliferation induced by L.p.+APCs or PHA by CD4
+CD25
+
cells. D. Inhibition of CD4
+CD25
2 cell IFN-c secretion induced by L.p.+APCs by CD4
+CD25
+ cells. 1:1 effector:Treg ratio could not be tested in 3 AI
because insufficient numbers of CD4
+CD25
+ cells were obtained (n=6 for AI and n=14 for CDL patients); *p,0.05, Mann-Whitney test. A and B show
means with SEM. C and D show the mean as a horizontal line.
doi:10.1371/journal.pntd.0001627.g002
Tregs in Dermal Leishmaniasis
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+CD25
+ cells at the end of treatment and 9 of 11
showed an increase in inhibition of IFN-c secretion (Figures 4D
and F). Inhibition of both parameters increased significantly for
the group as a whole, with the mean percent inhibition of
proliferation increasing from 21.9% to 46.5% (p=0.025,
Figure 4D) and the mean inhibition of IFN-c secretion rising
from 47.2% to 81.3% (p=0.007, Figure 4F). Suppression of
proliferation induced by PHA did not change significantly after
treatment (p=0.99; Figure 4E).
Expression of IDO in CDL Lesions Decreased after
Treatment and Was Correlated with IFNG Expression
The relative expression of FOXP3 and IL10 did not change
significantly after treatment of CDL (Figures 5A and C). The
relative expression of IFNG decreased in 8 out of 11 patients at the
end of treatment, with the mean value declining from 127.0680.3
to 24.367.9. However, this difference was not statistically
significant (p=0.148, Figure 5B). Finally, although the expression
of IDO in chronic lesions at the start of the study varied widely
between individuals, at the end of treatment the expression of this
gene was significantly downregulated from 10876601 to 154650
(p=0.037, Figure 5D). Because IDO expression in APCs is
upregulated by both inflammatory signals (particularly IFN-c)
[40,41] and Tregs (through CTLA4-B7 interactions) [42], we
examined whether IDO expression was correlated with that of
IFNG or FOXP3 in CDL lesions. Our analysis revealed a
significant positive correlation between IFNG and IDO expression.
In contrast, FOXP3 expression was not significantly correlated with
IDO expression (Figure 5E). Thus, IDO expression in the skin of
CDL patients was most likely upregulated by IFN-c.
Suppression in Co-Cultures of Effector CD4 T Cells and
Tregs Was Not Mediated by IL-10
To determine whether suppression of effector functions was
attributable to IL-10 secretion by CD4
+CD25
+ cells, we evaluated
IL-10 in the supernatants of the effector-Treg co-cultures. The
presence of CD4
+CD25
+ cells in the co-cultures did not result in
higher IL-10 concentrations in any of the study groups (Figure 6).
To the contrary, analysis of co-cultures at the 1:1 ratio (n=31) for
all groups revealed significantly lower IL-10 secretion in the
presence of CD4
+CD25
+ cells (Figure 6). Therefore, inhibition of
effector CD4 T cell functions in this in vitro system was not
attributable to IL-10 secretion by Tregs. Rather, these results
indicate that IL-10 secretion by CD4
+CD25
2 effector T cells and/
or APCs was also inhibited by Tregs.
Discussion
The regulation of adaptive immune responses is indispensable
for the effective clearance of antigen without harm to self tissues.
Although the importance of Tregs in this process is well
established, evaluation in human disease is challenging because
of the increasing recognition of the complexity of their phenotype
and function. To clarify the role of Tregs in the pathogenesis and
healing of DL caused by species of the Viannia subgenus, we
studied a cohort of subjects from an area in Colombia endemic for
L. panamensis and L. braziliensis. Comparisons of the frequency and
suppressive function of cells expressing Treg markers in peripheral
blood and the expression of genes related to inflammation and
regulation in the skin of AI and CDL patients, and CDL patients
before and after treatment, yielded evidence that Tregs participate
in clinical resistance/susceptibility and lesion healing.
Figure 3. Relative expression of FOXP3 is higher in leishmanin skin test (LST) sites from CDL patients. RNA was isolated from biopsies of
LST sites from AI (n=5) and CDL patients (n=7) and the expression of FOXP3 (A), IFNG (B), IL10 (C) and IDO (D) was measured by qRT-PCR. The
expression of each gene relative to healthy skin of four normal controls was calculated using the DDCT method. *p,0.05, unpaired t-test. The median
is represented by a horizontal line.
doi:10.1371/journal.pntd.0001627.g003
Tregs in Dermal Leishmaniasis
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frequency of CD25
hiFoxP3
+ CD4 T cells in their peripheral blood
than infected individuals who did not develop disease. Addition-
ally, FOXP3 expression was upregulated at skin sites of challenge
with leishmanin antigen only in CDL patients. These results are
consistent with several examples of chronic disease in which Foxp3
is upregulated in T cells [43–46] and previous reports of
infiltration of dermal lesions caused by L. guyanensis and L.
brazilienisis by Foxp3
+ cells [15,16,47] and upregulation of FOXP3
in lesions from post Kala Azar DL [48]. Foxp3 may therefore
constitute a marker for chronic DL caused by L. (Viannia) species.
Although CDL patients had higher numbers of CD25
hiFoxp3
+
cells in peripheral blood than AI, the capacity of their
CD4
+CD25
+ cells to inhibit pro-inflammatory IFN-c secretion
by effector T cells elicited by Leishmania antigens was lower. This
suggests that the CD25
hiFoxp3
+ cells that accounted for the higher
frequency in CDL patients are not specific for Leishmania antigens.
Since Foxp3 is a marker of natural Tregs generated in the thymus
after interaction with self antigens [37,51], these cells may be a
subset of Tregs specific for self antigens that are released during
the inflammatory response [7,52,53]. Alternatively, the higher
proportion of CD25
hiFoxp3
+ cells may reflect chronic activation in
CDL patients, since FoxP3 can be transiently expressed by
activated T cells [49,50]. However, we do not favor this
explanation because high expression of CD25 has been consis-
tently proven to be a marker of Tregs [31–34] and effector cells
expressing FoxP3 are mostly not CD25
hi [50]. Thus, we postulate
that CD25
hiFoxp3
+ Tregs, although more frequent in CDL, are
not responsible for the antigen specific suppression demonstrated
in the co-culture assays. Rather, this suppression is attributable to
a Leishmania-specific, Foxp3
2 subset. However, we cannot rule out
the possibility that Leishmania-specific effector cells acquired
resistance to regulation by Tregs after chronic antigenic
stimulation in CDL.
Clinical evaluation at the end of treatment with pentavalent
antimony showed that all patients had initiated a healing response.
Half had already healed completely while the other half showed
significant improvement ($50%, Table 1). Clinical follow-up was
possible for 7/11 patients at $13 weeks after starting treatment
and confirmed that all seven had completely healed (data not
shown). Thus, no evidence of treatment failure was seen in this
study cohort. The healing responses in this CDL cohort were
associated with significant increases in the frequency of
CD25
hiCD127
2 CD4 T cells in peripheral blood and in
Figure 4. Treg frequency and function increase after treatment of CDL. Frequency of cells with a Treg phenotype in PBMCs and suppressive
capacity of CD4
+CD25
+ cells were determined for CDL patients (n=11) before and after treatment. A. Frequency of CD4
+CD25
hiFoxp3
+ cells. B.
Frequency of CD4
+CD25
hiCD127
2 cells. C. Frequency of CD4
+CD25
hiGITR
+ cells. D. Inhibition of CD4
+CD25
2 cell proliferation by CD4
+CD25
+ cells at a
1:1 ratio after stimulation with L. panamensis (L.p.) and APCs. E. Inhibition of CD4
+CD25
2 cell proliferation by CD4
+CD25
+ cells at a 4:1 ratio after
stimulation with PHA. F. Inhibition of CD4
+CD25
2 cell IFN-c secretion by CD4
+CD25
+ cells at a 1:1 ratio after stimulation with L.p. and APCs. Inhibition
was calculated only for subjects that had proliferation and IFN-c levels above the average+2SD of control wells from the same co-culture (n=10 for
proliferation and 11 for IFN-c secretion with L.p. stimulation and n=11 for PHA stimulation). *p,0.05, paired t-test, **p,0.01, Wilcoxon signed-rank
test.
doi:10.1371/journal.pntd.0001627.g004
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CD4
+CD25
+ cells. In fact, of the 11 patients, 10 were able to
inhibit IFN-c secretion by $75% at the end of treatment and 9
showed an increase in CD4
+CD25
hiCD127
2 cells. Furthermore,
transcription of IFNG at the lesion site was not significantly
upregulated at the end of treatment, but rather decreased in 8 of
the 11 patients. Interestingly, we found that Foxp3 expression did
not change after treatment in CD4
+CD25
hi blood cells or at the
lesion site, suggesting that a Foxp3
+ subset of Tregs was not
responsible for the heightened suppression that was associated with
healing. Rather, these findings support the participation of a
CD127
2, Leishmania-specific subset of Tregs in the healing of
chronic dermal lesions caused by L. (Viannia).
Induction of Tregs during chronic infections is the result of
antigen presentation in a particular cytokine environment [7,53].
In the current study, parasite killing mediated by the anti-
leishmanial drug would presumably lead to release of antigens,
new antigen presentation events and Treg induction and/or
activation in the peripheral lymphoid organs [54]. Newly induced
Tregs would home to the lesion site to mitigate the inflammatory
response and aid in tissue repair. Homing of Tregs to the skin is
essential for the maintenance of skin homeostasis and for
suppression of Th1 cell-mediated responses [55,56]. Furthermore,
Tregs have been shown to contribute substantially to tissue repair
by providing regulation at sites of healing in many experimental
models. In an in vitro wound healing model, Tregs were shown to
counteract Th17 cell-mediated inhibition of fibroblast migration
into the wound [57], and tissue regeneration after kidney injury
was shown to depend on inhibition of pro-inflammatory cytokine
secretion by Tregs [58]. In another in vitro model, intact
extracellular matrix components that gradually replace inflamma-
tion-promoting fragmented components during tissue repair
Figure 5. Relative expression of IDO decreases in CDL patients after treatment and is correlated with IFNG. RNA was isolated from
biopsies of lesions from CDL patients (n=11) before and after treatment and the expression of FOXP3 (A), IFNG (B), IL10 (C) and IDO (D) was
measured by qRT-PCR. The expression of each gene relative to healthy skin of four normal controls was calculated using the DDCT method. E.
Correlation between the relative expression of IDO and FOXP3 (left panel) or IFNG (right panel). *p,0.05, Wilcoxon signed-rank test.
doi:10.1371/journal.pntd.0001627.g005
Tregs in Dermal Leishmaniasis
www.plosntds.org 8 April 2012 | Volume 6 | Issue 4 | e1627induce Tregs and activate their function [59]. Therefore, healing
of dermal lesions such as those present in CDL would likely benefit
from immune regulation by Tregs. Since all patients had initiated
a healing response at the end of treatment, our results are
consistent with the participation of a subset of Foxp3
2 CD127
2
Leishmania-specific Tregs in lesion resolution.
The limited absolute numbers of CD4
+CD25
+ cells allowed us
to test only two effector:Treg ratios. Significant differences in
antigen-specific suppression were detected at the 1:1 ratio, but
not at the 4:1 ratio. Since suppression by Tregs is activated
through cognate peptide/MHC-TCR interactions [60], the
inability to detect suppression at a higher ratio is probably due
to the expected low frequency of Leishmania-specific Tregs at the
outset of co-culture and the absence of proliferation by these cells
[61] (as evidenced by lack of variation in forward scatter, Figure
S 1 A ) .T h e r e f o r e ,e v e nt h o u g ht h en u m b e ro fLeishmania-specific
CD25
hi T cells in the co-culture is unknown, the observation of
significant suppression indicates that the number reached an
effective threshold under the assay conditions at a 1:1 ratio. In
addition, the CD4
+CD25
+ preparation includes activated
effector T cells that upregulate CD25 and, therefore, the
number of Tregs in the culture would have been diluted by
these cells. For these reasons, we believe that the suppression
observed in our system at a 1:1 ratio reflects the presence of
circulating antigen-specific Tregs that can contribute to the
mitigation of the inflammatory response upon homing to the
lesion site.
We examined the participation of IL-10 in the inhibition of
CD4 T cell effector functions in our co-cultures because this
cytokine is secreted by T cells with an effector phenotype in
intracellular parasitic infections [62–64] as well as by Tregs.
Furthermore, we have previously determined in a population from
the same region that IL-10 is expressed in susceptible individuals
and related to both development of CDL and IFN-c secretion [4].
Hence, it was conceivable that inhibition was due to IL-10
secretion by a CD25
+ activated effector population present in the
CD4
+CD25
+ preparation and not by Tregs. The diminished
production of IL-10 in co-cultures including CD4
+CD25
+ cells
demonstrated that IL-10 was not responsible for suppression by
these cells, supporting the interpretation that the observed
inhibition was indeed mediated by bona fide Tregs. We also
found that IL10 transcription was not significantly changed at the
lesion site immediately following treatment, suggesting that this
cytokine is not prominent in the healing process.
IDO is an enzyme expressed by APCs that metabolizes
tryptophan, an essential aminoacid for both lymphocyte prolif-
eration and parasite survival [38,39]. Hence, the expression of
IDO in leishmaniasis lesions may regulate the immune response
and aid in parasite eradication. Its expression is induced by
inflammatory cytokines, including IFN-c [40,41], and by Tregs
through interaction of CTLA-4 and B7 molecules [42].
Therefore, IDO transcription in the skin may reflect both the
inflammatory environment and Treg function. In this study, we
found that the expression of IDO was correlated with that of IFNG
and not to FOXP3 in CDL patients. This indicates that IDO
induction in APCs is not a likely mechanism of suppression used
by Tregs that infiltrate sites of ongoing immune responses to
Leishmania in CDL patients. Rather, IDO expression reflects the
reduced inflammatory environment present at these sites, which
is consistent with increased function of a subset of Tregs after
treatment.
The relatively small sample size limited our ability to detect
statistically significant differences in the expression of the genes
IFNG and IDO between AI (healing/clinical resistance) and
patients with chronic disease (non-healing/clinical susceptibility)
even though several of the latter showed marked upregulation.
Furthermore, although we did not determine the mechanism of
regulation by CD4
+CD25
+ cells, the results of functional as well as
phenotypic analyses provide compelling evidence of the partici-
pation of distinct Treg subsets in both pathogenesis and resolution
of CDL caused by Leishmania species of the (Viannia) subgenus.
Further characterization of these subsets is warranted since
immunotherapeutic strategies targeting these regulatory cells
could promote healing of recalcitrant presentations of leishman-
iasis.
Supporting Information
Figure S1 Gating strategy for analysis of CD4
+CD25
2
cell proliferation. CFSE labeled CD4
+CD25
2 cells were
cultured for 5 days with antigen presenting cells (APCs), L.
panamensis, CD4
+CD25
+ cells or PHA, as indicated. A. Gates for
CFSE labeled cells were determined in the CD4
+ region to exclude
unlabeled cells from the analysis. B. Regions for the proliferating
populations were drawn in the CFSE labeled gate based on the
peaks induced by PHA and used to calculate the proliferation
index (PI) with the formula PI=S(% in region62
n21), where n is
the region number. One representative subject is shown.
(TIF)
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